Risk-benefit assessment and value of beta-2-sympathomimetic drugs in asthma therapy
Schulz, V.; Ulmer, W.T.; Kleinsorge, H.
Pneumologie 46(8): 315-321
1992
ISSN/ISBN: 0934-8387 PMID: 1357653 Document Number: 393834
Document emailed within 1 workday
Related Documents
Criée, C.P.; Laier-Groeneveld, G. 1995: Beta 2-sympathomimetic drugs Der Internist 36(9): 918-923Hoffarth, H.P.; Freyberger, H.; Völkl, K.P.; Ulmer, W.T. 1990: Inhalation therapy with selective beta 2-sympathomimetic drugs. Effect of pirbuterol administered via the Autohaler and salbutamol administered via the Diskhaler in obstructive respiratory tract disease Fortschritte der Medizin 108(8): 162-164
Bascuñana, H.; Villarreal, I.; Alfonso, S.; Terré, R.; Bernabeu, M. 2000: Agitation in head injury. II. Treatment with antidepressant, sympathomimetic, beta blocker , dopaminergic and other drugs Revista de Neurologia 30(11): 1044-1047
Janson, C.; Boman, G.; Boe, J. 1992: Which patients benefit from adding theophylline to beta 2-agonist treatment in severe acute asthma? Annals of Allergy 69(2): 107-110
Yonga, G.O.; Oyuga, H.W.; Njeru, E.K. 1993: Influence of beta-blockade with beta-1-selectivity or intrinsic sympathomimetic activity on some cardiorespiratory responses to exercise East African Medical Journal 70(7): 405-408
Fenner, H. 1992: Nonsteroidal antiinflammatory drugs: benefit/risk evaluation in rheumatic diseases Journal of Rheumatology. Suppl 32: 98-99
Rubinow, A.; Leshem-Rubinow, E. 2007: Risk-benefit assessment in determining decision-making capacity Harefuah 146(7): 563
Dull, H.B. 1979: Cell substrates. their use in the production of vaccines and other biologicals. Benefit-risk assessment Advances in Experimental Medicine and Biology 118: 187-193
Rios, N.; Adaskina, N.; Frömke, C.; Papendorf, F.; Schippert, C.; Koch, A.; Hillemanns, P.; Park-Simon, T-Won. 2016: The Benefit of Baseline Staging-Risk Assessment of Distant Breast Cancer Metastases by Tumor Stage Anticancer Research 36(9): 4909-4914
Seebacher, C. 1986: Comparison of benefit against risk of ketoconazole therapy Therapia Hungarica 34(4): 227-232
Davidson, B.A.; Moorman, P.G. 2014: Risk-benefit assessment of the combined oral contraceptive pill in women with a family history of female cancer Expert Opinion on Drug Safety 13(10): 1375-1382
Cheetham, T.Craig.; Levy, G.; Spence, M. 2003: Predicting the risk of gastrointestinal bleeding due to nonsteroidal antiinflammatory drugs: NSAID electronic assessment of risk Journal of Rheumatology 30(10): 2241-2244
Rosner, F. 1984: Risk-benefit ratio: hazardous surgery and experimental therapy Mount Sinai Journal of Medicine new York 51(1): 58-59
Gerner, R. 1985: Sympathomimetic drugs and lung surfactant factor Journal of Perinatal Medicine 13(6): 317-318
Ojewole, J.A.; Akinwande, K.I. 1984: Effects of sympathomimetic drugs on reptilian atrial muscles Methods and Findings in Experimental and Clinical Pharmacology 6(5): 245-253
Seyberth, H.W.; Rahn, K.H. 1973: Pharmacokinetic studies in man with a beta-sympathomimetic drug used as aerosol Verhandlungen der Deutschen Gesellschaft für Innere Medizin 79: 888-891
Zhang, Y. 2002: Further recognize the benefit and risk of postmenopausal hormone replacement therapy on atherosclerotic cardiovascular diseases Zhonghua Fu Chan Ke Za Zhi 37(6): 321-323
Zarranz Imirizaldu, J.J. 1997: Anti-aggregation therapy for prevention of cerebral ischemic stroke: a risk benefit analysis Medicina Clinica 109(20): 802-807
Miwa, T.; Fukagawa, K.; Tokoro, T. 1988: The effect of sympathomimetic and sympatholytic drugs upon resting point of accommodation Nippon Ganka Gakkai Zasshi 92(7): 1235-1241
Grüneberger, A.; Geier, G. 1981: Treatment of motor urge incontinence with the beta 2-sympathomimetic drug clenbuterol Der Urologe. Ausg. a 20(3): 153-154